Oncotarget

Research Papers:

A novel combinatorial treatment option for metastatic uveal melanoma

Dudi Shneor, Shay Tayeb, Jacob Pe'er, Hanna Voropaev, Maria Gimmelshein, Nathalie Cassoux, Alik Honigman and Shahar Frenkel _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:26096-26108. https://doi.org/10.18632/oncotarget.25445

Metrics: PDF 649 views  |   HTML 977 views  |   ?  


Abstract

Dudi Shneor1,2, Shay Tayeb1,3, Jacob Pe’er2, Hanna Voropaev1,2, Maria Gimmelshein1,2, Nathalie Cassoux4,5, Alik Honigman1,3,* and Shahar Frenkel2,*

1Department of Biochemistry and Molecular Biology, IMRIC, The Hebrew University-Hadassah Medical School, Jerusalem, Israel

2Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

3Hadassah Academic College, Jerusalem, Israel

4Department of Ocular Oncology, Institut Curie, Paris, France

5Université Paris V Descartes, Paris, France

*These authors have contributed equally to this work

Correspondence to:

Shahar Frenkel, email: shahar.frenkel@gmail.com

Keywords: cancer; chemotherapy; replicative competent retroviruses (RCR); CREB; combinatorial targeted treatment

Received: February 16, 2018    Accepted: April 28, 2018    Published: May 25, 2018

ABSTRACT

Uveal melanoma (UM) is the most frequent intraocular tumor in adult patients. When metastases occur, systemic therapy with alkylating agents (fotemustine or dacarbazine (DTIC)) has shown only modest efficacy. The common chemotherapeutic drug doxorubicin (DOX) is not used to treat metastatic UM (mUM). To expand the chemotherapeutic arsenal for mUM, we tested the effect of DOX on UM cell mortality. We have previously shown that CREB knockdown enhances sensitivity to DOX. UM cells infected with recombinant MuLV-based replicative competent retroviruses (RCR) expressing shRNA targeting CREB were co-treated with either DTIC or DOX. We found that CREB knockdown increases the sensitivity of these cells to both DOX and DTIC in normoxia and more so in hypoxia as measured by cell survival and Caspase 3 activation. The ability to combine CREB knockdown by infection with the RCR recombinant virus which preferentially infects replicating tumor cells and chemotherapy to achieve the same amount of cell death in lower concentrations may result in fewer side effects of the drugs. This combination is a possible new treatment for mUM.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25445